Literature DB >> 11310605

Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?

C T Supuran1, F Briganti, S Tilli, W R Chegwidden, A Scozzafava.   

Abstract

Novel sulfonamide inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) were prepared by reaction of aromatic or heterocyclic sulfonamides containing amino, imino, or hydrazino moieties with N,N-dialkyldithiocarbamates in the presence of oxidizing agents (sodium hypochlorite or iodine). The N,N-dialkylthiocarbamylsulfenamido-sulfonamides synthesized in this way behaved as strong inhibitors of human CA I and CA II (hCA I and hCA II) and bovine CA IV (bCA IV). For the most active compounds, inhibition constants ranged from 10(-8) to 10(-9) M (for isozymes II and IV). Three of the derivatives belonging to this new class of CA inhibitors were also tested as inhibitors of tumor cell growth in vitro. These sulfonamides showed potent inhibition of growth against several leukemia, non-small cell lung, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. With several cell lines. GI50 values of 10-75 nM were observed. The mechanism of antitumor action with the new sulfonamides reported here remains obscure, but may involve inhibition of CA isozymes which predominate in tumor cell membranes (CA IX and CA XII), perhaps causing acidification of the intercellular milieu, or inhibition of intracellular isozymes which provide bicarbonate for the synthesis of nucleotides and other essential cell components (CA II and CA V). Optimization of these derivatives from the SAR point of view, might lead to the development of effective novel types of anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310605     DOI: 10.1016/s0968-0896(00)00288-1

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  40 in total

1.  Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line.

Authors:  Carsten Uhd Nielsen; Claudiu T Supuran; Andrea Scozzafava; Sven Frokjaer; Bente Steffansen; Birger Brodin
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.

Authors:  Xiaotong Hu; Zhongting Huang; Zhongcai Liao; Chao He; Xiao Fang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  Expression of hypoxia-inducible carbonic anhydrases in brain tumors.

Authors:  Martin A Proescholdt; Christina Mayer; Marion Kubitza; Thomas Schubert; Shu-Yuan Liao; Eric J Stanbridge; Sergey Ivanov; Edward H Oldfield; Alexander Brawanski; Marsha J Merrill
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

4.  Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.

Authors:  Joonas Haapasalo; Kristiina Nordfors; Sally Järvelä; Helena Bragge; Immo Rantala; Anna-Kaisa Parkkila; Hannu Haapasalo; Seppo Parkkila
Journal:  Neuro Oncol       Date:  2007-04-13       Impact factor: 12.300

5.  Gastric pit cell hyperplasia and glandular atrophy in carbonic anhydrase IX knockout mice: studies on two strains C57/BL6 and BALB/C.

Authors:  Mari Leppilampi; Tuomo J Karttunen; Jyrki Kivelä; Marta Ortova Gut; Silvia Pastoreková; Jaromir Pastorek; Seppo Parkkila
Journal:  Transgenic Res       Date:  2005-10       Impact factor: 2.788

6.  Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties.

Authors:  Caroli Genis; Katherine H Sippel; Nicolette Case; Wengang Cao; Balendu Sankara Avvaru; Lawrence J Tartaglia; Lakshmanan Govindasamy; Chingkuang Tu; Mavis Agbandje-McKenna; David N Silverman; Charles J Rosser; Robert McKenna
Journal:  Biochemistry       Date:  2009-02-17       Impact factor: 3.162

7.  The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.

Authors:  Kristiina Nordfors; Joonas Haapasalo; Miikka Korja; Anssi Niemelä; Jukka Laine; Anna-Kaisa Parkkila; Silvia Pastorekova; Jaromir Pastorek; Abdul Waheed; William S Sly; Seppo Parkkila; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2010-04-18       Impact factor: 4.430

8.  N-[4-Acetyl-5-(3-methoxy-phen-yl)-4,5-dihydro-1,3,4-thia-diazol-2-yl]acetamide.

Authors:  G Aridoss; S Amirthaganesan; D Velmurugan; S H Kim; Y T Jeong
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-10-11

9.  Carbonic anhydrase isozymes IX and XII in gastric tumors.

Authors:  Mari Leppilampi; Juha Saarnio; Tuomo J Karttunen; Jyrki Kivelä; Silvia Pastoreková; Jaromir Pastorek; Abdul Waheed; William S Sly; Seppo Parkkila
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

10.  Novel organometallic cationic ruthenium(II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase.

Authors:  Bradley T Loughrey; Michael L Williams; Peter C Healy; Alessio Innocenti; Daniela Vullo; Claudiu T Supuran; Peter G Parsons; Sally-Ann Poulsen
Journal:  J Biol Inorg Chem       Date:  2009-04-24       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.